Wegovy vs Mounjaro: Which Mechanism Works for You?
Understanding Ozempic Versus Wegovy and Mounjaro Treatment Mechanisms
When comparing ozempic versus wegovy and Mounjaro options, the fundamental difference lies in their active ingredients and receptor targeting. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro, however, contains tirzepatide—a dual agonist that targets both GIP and GLP-1 receptors, offering a different approach to weight management through its unique mechanism.
Both prescription-only medicines work alongside a reduced-calorie diet and increased physical activity, but their different pathways mean individual responses may vary. Wegovy has established clinical evidence from the STEP trial programme, whilst Mounjaro brings its dual-receptor approach from the SURMOUNT studies. At EverydayMeds, registered with GPhC #9012878, we offer both treatments so your prescriber can recommend the most appropriate option based on your clinical assessment and individual circumstances.
Wegovy vs Mounjaro Pricing and Value Comparison
Understanding the cost differences when evaluating ozempic versus wegovy and Mounjaro treatments helps inform your decision. Wegovy follows a 5-dose escalation schedule starting at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles offer convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, providing your first 8 weeks in one order.
New customers benefit from code FIRST40 applied at checkout, whilst returning customers use DOSE25 to reach these final prices. Mounjaro follows a different pricing structure with its 6-dose escalation from 2.5mg to 15mg, reflecting its distinct dosing approach. Both treatments are available through our streamlined ordering process, with expert clinical assessment ensuring you receive the most appropriate prescription-only medicine for your weight management journey.
Clinical Evidence: STEP Trials and Wegovy Performance
When researching ozempic versus wegovy comparisons, it's important to understand that Wegovy's clinical evidence comes from the comprehensive STEP trial programme. In STEP 1, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 demonstrated effectiveness in patients with type 2 diabetes, showing average weight loss of 9.6%.
The SELECT cardiovascular outcomes study showed a 20% reduction in major cardiovascular events, highlighting potential benefits beyond weight management. However, individual results may vary, and weight management requires long-term commitment—STEP 1 extension data showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising the importance of sustained therapy.
How Wegovy Works: GLP-1 Receptor Mechanism Explained
Understanding Wegovy's mechanism helps clarify the ozempic versus wegovy discussion, particularly since both contain semaglutide but are licensed for different indications. Wegovy works as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally released by your intestines after eating. This mechanism reduces appetite by acting on brain appetite centres, particularly in the hypothalamus, whilst also slowing gastric emptying to promote feelings of fullness after smaller meals. The treatment may also reduce food cravings and thoughts about food, supporting adherence to reduced-calorie eating plans. This once-weekly injection is delivered via Novo Nordisk's FlexTouch pen, designed for self-administration with minimal discomfort.
EverydayMeds Ordering Process: Assessment to Delivery
Our streamlined process makes accessing Wegovy or Mounjaro straightforward when you're comparing ozempic versus wegovy options. Complete our 3-minute online clinical assessment, providing medical history and current medications to ensure safe prescribing. Our qualified prescribers, working within GPhC #9012878 guidelines, review your assessment within 3 working days (or 24 hours with express service) to determine the most appropriate treatment. Once approved, your prescription-only medicine is dispensed and dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. All treatments arrive in discreet, insulated packaging with clear instructions for storage and administration.
Storage and Practical Considerations for Treatment Success
Practical factors often influence the ozempic versus wegovy decision, particularly storage requirements for busy lifestyles. Wegovy must be stored in the fridge at 2-8°C before first use, but offers a significant advantage with 6 weeks of room temperature stability below 30°C once removed from refrigeration. This extended room temperature tolerance exceeds Mounjaro's 21-day limit, making Wegovy more suitable for extended travel or flexible storage needs. The FlexTouch pen delivers precise doses through its dose escalation schedule—starting at 0.25mg for weeks 1-4, then increasing every 4 weeks until reaching the 2.4mg maintenance dose. Each pen contains 4 doses, clearly marked with dose confirmation windows for accurate administration.
Wegovy vs Mounjaro: Dosing Schedules and Escalation Patterns
The dosing comparison between treatments reveals important differences when evaluating ozempic versus wegovy and Mounjaro options. Wegovy follows a 5-step escalation over 16 weeks: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance from week 17 onwards. Mounjaro uses a 6-step protocol with different increments: 2.5mg starting dose, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to 15mg maximum maintenance dose.
Both require mandatory dose escalation—you cannot skip steps or start at higher doses due to gastrointestinal tolerability concerns. The gradual increase helps minimise side effects whilst achieving therapeutic effectiveness. Your prescriber will determine the optimal escalation pace based on your tolerance and response, potentially extending certain dose phases if needed for better adaptation.
Why EverydayMeds Offers Both Wegovy and Mounjaro Options
Our unique position offering both treatments when patients search "ozempic versus wegovy" reflects our commitment to personalised medicine rather than promoting single solutions. Different patients respond better to different mechanisms—some may find Wegovy's GLP-1 approach more suitable, whilst others might benefit from Mounjaro's dual GIP/GLP-1 action. Clinical factors including diabetes status, previous treatment responses, and individual tolerability profiles all influence prescriber recommendations. Rather than limiting choice, we provide access to both leading prescription-only medicines, supported by expert clinical assessment and ongoing monitoring. This approach ensures you receive the most appropriate treatment based on evidence and individual circumstances, not arbitrary limitations. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which is right for you based on your complete medical picture and treatment goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
